Nevertheless, and due to their short-term pro-inflammatory impact, the administration of PS-IONPs should prospectively be applied with caution in patients with inflammatory diseases of the liver, such as hepatitis or metabolic disorders, since NF-κB signalling is required for inflammatory processes as well as for several other liver cell functions. This evidence concerns the gene NFKB1 and Other metabolic disease.